JP2005531589A5 - - Google Patents

Download PDF

Info

Publication number
JP2005531589A5
JP2005531589A5 JP2004508106A JP2004508106A JP2005531589A5 JP 2005531589 A5 JP2005531589 A5 JP 2005531589A5 JP 2004508106 A JP2004508106 A JP 2004508106A JP 2004508106 A JP2004508106 A JP 2004508106A JP 2005531589 A5 JP2005531589 A5 JP 2005531589A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
formula
inhibitors
pharmaceutically acceptable
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004508106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/016524 external-priority patent/WO2003099851A2/en
Publication of JP2005531589A publication Critical patent/JP2005531589A/ja
Publication of JP2005531589A5 publication Critical patent/JP2005531589A5/ja
Pending legal-status Critical Current

Links

JP2004508106A 2002-05-24 2003-05-23 Hivの複製を阻害するための方法及び組成物 Pending JP2005531589A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38340902P 2002-05-24 2002-05-24
PCT/US2003/016524 WO2003099851A2 (en) 2002-05-24 2003-05-23 Methods and compositions for inhibiting hiv replication

Publications (2)

Publication Number Publication Date
JP2005531589A JP2005531589A (ja) 2005-10-20
JP2005531589A5 true JP2005531589A5 (cg-RX-API-DMAC10.html) 2010-08-12

Family

ID=29584565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004508106A Pending JP2005531589A (ja) 2002-05-24 2003-05-23 Hivの複製を阻害するための方法及び組成物

Country Status (6)

Country Link
US (1) US20060068389A1 (cg-RX-API-DMAC10.html)
EP (1) EP1523328A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005531589A (cg-RX-API-DMAC10.html)
AU (1) AU2003234637B2 (cg-RX-API-DMAC10.html)
CA (1) CA2487655A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003099851A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071063B2 (en) * 2008-02-21 2011-12-06 Exxonmobile Research And Engineering Company Separation of hydrogen from hydrocarbons utilizing zeolitic imidazolate framework materials

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201819A (ja) * 1985-11-13 1987-09-05 Res Dev Corp Of Japan 免疫不全症処置剤
AU8166191A (en) * 1990-08-10 1992-02-13 Ortho Pharmaceutical Corporation Method for treatment of bone wasting diseases
US5874225A (en) * 1993-02-19 1999-02-23 Trustees Of The University Of Pennsylvania Identification of compounds that modulate HIV-1 vpr protein activity
AU1373395A (en) * 1993-12-15 1995-07-03 Trustees Of The University Of Pennsylvania, The Vpr receptor protein
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
JPH08239306A (ja) * 1995-03-03 1996-09-17 Sunstar Inc 忌避剤
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
AUPQ127399A0 (en) * 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis

Similar Documents

Publication Publication Date Title
US11773098B2 (en) Solid forms of a toll-like receptor modulator
US20240180948A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11660307B2 (en) Methods for treating SARS CoV-2 infections
Paintsil et al. Antiviral agents
ES2995458T3 (en) N4-hydroxycytidine derivative and anti-viral uses related thereto
JP2020183407A (ja) Hivを治療するためのトール様受容体の調節因子
JP2017203033A5 (cg-RX-API-DMAC10.html)
RU2012101881A (ru) Производные азапептидов
CN104244947A (zh) 用于治疗hcv的方法和组合物
ES2844629T3 (es) Tratamiento de la infección por el virus de la hepatitis delta
ES2797900T3 (es) Compuestos y combinaciones para el tratamiento del VIH
JP2018512428A5 (cg-RX-API-DMAC10.html)
US20050009768A1 (en) Use of ribofuranose derivatives against inflammatory bowel diseases
WO2021130195A1 (en) Method of treating virus infection using a tlr7 agonist
Burrell et al. Antiviral chemotherapy
CN111587107B (zh) 药物组合物
JP2005500981A5 (cg-RX-API-DMAC10.html)
Ekmekyapar et al. Antiviral drugs and their toxicities
Asmar et al. Antiviral therapy: Respiratory infections, chornic hepatitis
Shelton Chutes and ladders in hepatitis C nucleoside drug development
Quan Pharmacotherapy of hepatitis B infection: a brief review
US10851125B2 (en) Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
HK1239685B (en) Solid forms of a toll-like receptor modulator
HK1239685A1 (en) Solid forms of a toll-like receptor modulator